Literature DB >> 7791040

Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection.

T M Ludden1, S L Beal, L B Sheiner.   

Abstract

In pharmacokinetic data analysis, it is frequently necessary to select the number of exponential terms in a polyexponential expression used to describe the concentration-time relationship. The performance characteristics of several selection criteria, the Akaike Information Criterion (AIC), and the Schwarz Criterion (SC), and the F test (alpha = 0.05), were examined using Monte Carlo simulations. In particular, the ability of these criteria to select the correct model, to select a model allowing estimation of pharmacokinetic parameters with small bias and good precision, and to select a model allowing precise predictions of concentration was evaluated. To some extent interrelationships among these procedures is explainable. Results indicate that the F test tends to choose the simpler model more often than does either the AIC or SC, even when the more complex model is correct. Also, the F test is more sensitive to deficient sampling designs. Clearance estimates are generally very robust to the choice of the wrong model. Other pharmacokinetic parameters are more sensitive to model choice, particularly the apparent elimination rate constant. Prediction of concentrations is generally more precise when the correct model is chosen. The tendency for the F test (alpha = 0.05) to choose the simpler model must be considered relative to the objectives of the study.

Mesh:

Year:  1994        PMID: 7791040     DOI: 10.1007/bf02353864

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  8 in total

1.  Do you need a pharmacokinetic model, and, if so, which one?

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

2.  Efficiency of different criteria for selecting pharmacokinetic multiexponential equations.

Authors:  B P Imbimbo; P Martinelli; M Rocchetti; G Ferrari; G Bassotti; E Imbimbo
Journal:  Biopharm Drug Dispos       Date:  1991-03       Impact factor: 1.627

3.  Some clarifications regarding moments of residence times with pharmacokinetic models.

Authors:  S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

4.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  A new criterion for selection of pharmacokinetic multiexponential equations.

Authors:  B P Imbimbo; E Imbimbo; S Daniotti; D Verotta; G Bassotti
Journal:  J Pharm Sci       Date:  1988-09       Impact factor: 3.534

6.  Use of the F test for determining the degree of enzyme-kinetic and ligand-binding data. A Monte Carlo simulation study.

Authors:  F J Burguillo; A J Wright; W G Bardsley
Journal:  Biochem J       Date:  1983-04-01       Impact factor: 3.857

7.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

8.  Numerical deconvolution by least squares: use of prescribed input functions.

Authors:  D J Cutler
Journal:  J Pharmacokinet Biopharm       Date:  1978-06
  8 in total
  96 in total

1.  Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.

Authors:  S Appel-Dingemanse; M O Lemarechal; A Kumle; M Hubert; E Legangneux
Journal:  Br J Clin Pharmacol       Date:  1999-05       Impact factor: 4.335

2.  Pharmacokinetics of xanthohumol and metabolites in rats after oral and intravenous administration.

Authors:  LeeCole Legette; Lian Ma; Ralph L Reed; Cristobal L Miranda; John Mark Christensen; Rosita Rodriguez-Proteau; Jan F Stevens
Journal:  Mol Nutr Food Res       Date:  2011-12-07       Impact factor: 5.914

3.  Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.

Authors:  Yoshiyuki Shirasaka; Takanori Mori; Yukiko Murata; Takeo Nakanishi; Ikumi Tamai
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

4.  Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Authors:  Henry S Heine; Arnold Louie; Jeffrey J Adamovicz; Kei Amemiya; Randy L Fast; Lynda Miller; Steven M Opal; John Palardy; Nicolas A Parejo; Fritz Sörgel; Martina Kinzig-Schippers; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

5.  Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats.

Authors:  Byung-Yo Lee; Kwang-Il Kwon; Min-Soo Kim; In-Hwan Baek
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-03-01       Impact factor: 2.441

6.  Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations.

Authors:  Elena Soto; Sebastian Haertter; Michael Koenen-Bergmann; Alexander Staab; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2009-12-29       Impact factor: 4.200

7.  Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.

Authors:  Iñaki F Trocóniz; Josep-María Cendrós; Concepción Peraire; Joaquim Ramis; Maria J Garrido; Paolo F Boscani; Rosendo Obach
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir.

Authors:  Fenglei Huang; Kristin Drda; Thomas R MacGregor; Joseph Scherer; Lois Rowland; Thuy Nguyen; Charles Ballow; Mark Castles; Patrick Robinson
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Dermal, subdermal, and systemic concentrations of granisetron by iontophoretic delivery.

Authors:  Ayyappa Chaturvedula; Dipty P Joshi; Carter Anderson; Russ Morris; Walter L Sembrowich; Ajay K Banga
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

10.  Joint population pharmacokinetic/pharmacodynamic model for the heart rate effects at rest and at the end of exercise for cilobradine.

Authors:  Nieves Vélez de Mendizábal; Alexander Staab; Hans Günter Schäfer; Dirk Trommeshauser; Christiane Döge; Matthias Klüglich; Juliet Roberts; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2012-12-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.